Monitoring late-onset toxicities in phase I trials using predicted risks
From MaRDI portal
Publication:3526173
DOI10.1093/biostatistics/kxm044zbMath1143.62072OpenAlexW2167561655WikidataQ35804231 ScholiaQ35804231MaRDI QIDQ3526173
B. Nebiyou Bekele, Yu Shen, Peter F. Thall, Yuan Ji
Publication date: 25 September 2008
Published in: Biostatistics (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1093/biostatistics/kxm044
Markov chain Monte Carlolatent variablesBayesian inferenceisotonic regressionadaptive designdose findingpredictive probabilityordinal modeling
Applications of statistics to biology and medical sciences; meta analysis (62P10) Bayesian inference (62F15) Medical applications (general) (92C50)
Related Items
Review of Statistical Treatment for Oncology Dose-Escalation Trial with Prolonged Evaluation Window or Fast Enrollment, Time-to-event continual reassessment method incorporating treatment cycle information with application to an oncology phase I trial, Adaptive isotonic estimation of the minimum effective and peak doses in the presence of covariates, Bayesian models and decision algorithms for complex early phase clinical trials, The adaptive accelerated biased coin design for phase I clinical trials, Adaptive clinical trial designs for phase I cancer studies, Risk-Group-Specific Dose Finding Based on an Average Toxicity Score, Using Joint Utilities of the Times to Response and Toxicity to Adaptively Optimize Schedule–Dose Regimes
